Special clinical considerations of beta-blocker treatment

Clyde W. Yancy*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Outcomes for heart failure have improved considerably with the implementation of neurohormonal antagonism that includes angiotensin-converting enzyme inhibitors and β-blockers. Despite the robust benefit of β-blockers for heart failure, it is not clear that the benefit can be extended to all patient groups. Special clinical consideration thus needs to be given to the elderly, women, and African Americans. A retrospective review of available data suggests that despite differences in the natural history of heart failure for these groups, significant benefit can still be expected from the use of β-blockers for heart failure. Future trials will address these groups in a prospective manner.

Original languageEnglish (US)
Pages (from-to)S27-S35
JournalReviews in Cardiovascular Medicine
Issue numberSUPPL. 3
StatePublished - Oct 12 2002


  • African Americans
  • Beta-blockers
  • Elderly
  • Heart failure
  • Special populations
  • Women

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Special clinical considerations of beta-blocker treatment'. Together they form a unique fingerprint.

Cite this